ZA201303390B - Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same - Google Patents

Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same

Info

Publication number
ZA201303390B
ZA201303390B ZA2013/03390A ZA201303390A ZA201303390B ZA 201303390 B ZA201303390 B ZA 201303390B ZA 2013/03390 A ZA2013/03390 A ZA 2013/03390A ZA 201303390 A ZA201303390 A ZA 201303390A ZA 201303390 B ZA201303390 B ZA 201303390B
Authority
ZA
South Africa
Prior art keywords
same
vaccine
nucleic acid
acid molecule
molecule encoding
Prior art date
Application number
ZA2013/03390A
Other languages
English (en)
Inventor
Mathura P Ramanathan
Bernadette Ferraro
Jian Yan
Niranjan Y Sardesai
David B Weiner
Original Assignee
Inovio Pharmaceuticals Inc
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inovio Pharmaceuticals Inc, Univ Pennsylvania filed Critical Inovio Pharmaceuticals Inc
Publication of ZA201303390B publication Critical patent/ZA201303390B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y116/00—Oxidoreductases oxidizing metal ions (1.16)
    • C12Y116/01—Oxidoreductases oxidizing metal ions (1.16) with NAD+ or NADP+ as acceptor (1.16.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17021—Glutamate carboxypeptidase II (3.4.17.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21077—Semenogelase (3.4.21.77), i.e. prostate specific antigen or PSA or kallikrein 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2013/03390A 2010-11-12 2013-05-09 Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same ZA201303390B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41317610P 2010-11-12 2010-11-12
US41781710P 2010-11-29 2010-11-29
PCT/US2011/060592 WO2012065164A2 (en) 2010-11-12 2011-11-14 Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same

Publications (1)

Publication Number Publication Date
ZA201303390B true ZA201303390B (en) 2016-02-24

Family

ID=46051609

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/03390A ZA201303390B (en) 2010-11-12 2013-05-09 Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same

Country Status (16)

Country Link
US (6) US8927692B2 (https=)
EP (3) EP3536703B1 (https=)
JP (7) JP6077450B2 (https=)
KR (5) KR102557275B1 (https=)
CN (2) CN106434676B (https=)
AU (1) AU2011325893B2 (https=)
BR (1) BR112013011705B1 (https=)
CA (1) CA2817709C (https=)
DK (1) DK2638055T3 (https=)
EA (1) EA027315B1 (https=)
ES (1) ES2718846T3 (https=)
MX (3) MX358725B (https=)
PL (1) PL3536703T3 (https=)
SI (1) SI3536703T1 (https=)
WO (1) WO2012065164A2 (https=)
ZA (1) ZA201303390B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
JP6077450B2 (ja) * 2010-11-12 2017-02-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
RU2737765C2 (ru) * 2012-05-04 2020-12-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
CN104812401B (zh) * 2012-12-13 2017-10-13 宾夕法尼亚大学理事会 Wt1疫苗
WO2014093894A2 (en) * 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
KR20150130284A (ko) * 2013-03-15 2015-11-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 백신 및 이를 이용한 치료 방법
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015063647A1 (en) * 2013-11-01 2015-05-07 Pfizer Inc. Vectors for expression of prostate-associated antigens
PL4023249T3 (pl) 2014-04-23 2025-03-10 Modernatx, Inc. Szczepionki z kwasem nukleinowym
MX2017007187A (es) 2014-12-01 2018-01-30 Univ Pennsylvania Construcciones de anticuerpos de adn y metodo para utilizarlas.
MA42543A (fr) 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques
AU2016341309A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Cancer vaccines
KR20180138204A (ko) * 2016-03-21 2018-12-28 데이비드 비. 웨이너 Dna 항체 작제물 및 이의 사용 방법
EP3463450A4 (en) * 2016-06-03 2020-07-29 Etubics Corporation COMPOSITIONS AND METHODS OF ANTI-TUMOR VACCINATION USING ANTIGENS ASSOCIATED WITH PROSTATE CANCER
CN106119231A (zh) * 2016-06-24 2016-11-16 安徽未名细胞治疗有限公司 一种肿瘤抗原psa的ctl识别表位肽及其应用
CN106581668B (zh) * 2016-12-31 2020-03-24 广州姿生生物科技有限公司 一种抗原表位肽组合物及其应用
CA3083532C (en) * 2017-12-13 2023-09-05 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting prame and uses thereof
CN111308327B (zh) * 2019-12-02 2021-01-26 电子科技大学 模拟电路故障定位与故障元件参数辨识方法
US20250269010A1 (en) * 2021-02-05 2025-08-28 St Pharm Co., Ltd. Novel nucleic acid molecule
IT202400001212A1 (it) 2024-01-23 2025-07-23 Pratrivero S P A Manufatto tessile predisposto per il riciclo e metodo per la produzione di tale manufatto

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US5643579A (en) 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US4790987A (en) 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
WO1990010693A1 (en) 1989-03-08 1990-09-20 Health Research, Inc. Recombinant poxvirus host selection system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
ES2090129T3 (es) 1989-03-31 1996-10-16 Univ Washington Vacunas que contienen microorganismos tipo phop avirulentos.
EP0431668B1 (en) 1989-12-04 1995-02-15 Akzo Nobel N.V. Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
DE69334071T2 (de) * 1992-11-05 2007-10-25 Sloan-Kettering Institute For Cancer Research Prostata-spezifisches membranantigen
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
HU219767B (hu) 1993-01-26 2001-07-30 Leslie R. Coney Készítmények és eljárások genetikai anyag sejtbe történő beviteléhez
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1994028929A1 (en) 1993-06-07 1994-12-22 Genentech, Inc. Hiv envelope polypeptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
US6630305B1 (en) * 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
CA2285056C (en) 1997-04-03 2004-12-14 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
AU8444798A (en) 1997-06-30 1999-01-25 Centre National De La Recherche Scientifique Improved method for transferring nucleic acid into the striped muscle and combination therefor
EP1086223B1 (en) 1998-06-01 2009-07-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US6833438B1 (en) * 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6697669B2 (en) 1998-07-13 2004-02-24 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6136703A (en) 1998-09-03 2000-10-24 Micron Technology, Inc. Methods for forming phosphorus- and/or boron-containing silica layers on substrates
SK4272001A3 (en) * 1998-10-05 2003-02-04 Pharmexa As Methods for therapeutic vaccination
US6589529B1 (en) 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
WO2001025272A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US20020081680A1 (en) * 2000-04-17 2002-06-27 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
EP2287186B1 (en) 2001-09-06 2014-12-31 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
MXPA05001933A (es) 2002-08-19 2005-04-28 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
MXPA05004860A (es) 2002-11-04 2005-08-18 Advisys Inc Promotores musculares sinteticos con actividades que exceden las secuencias reguladoras de origen natural en las celulas cardiacas.
CA2526274C (en) * 2003-05-30 2015-12-01 Agensys, Inc. Prostate stem cell antigen (psca) variants and subsequences thereof
WO2004108260A2 (en) 2003-05-30 2004-12-16 Advisys, Inc. Devices and methods for biomaterial production
DE602005017743D1 (de) * 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
AU2005249450A1 (en) * 2004-05-27 2005-12-15 Centocor, Inc. Cynomolgus prostate specific antigen
KR100647847B1 (ko) * 2005-05-27 2006-11-23 크레아젠 주식회사 인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 및 치료 효능을 분석하는 방법
JP2008546788A (ja) * 2005-06-21 2008-12-25 サイト パルス サイエンシズ、インコーポレイテッド 前立腺癌に対するワクチンに関する方法及び組成物
KR101357685B1 (ko) 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
BRPI0717638A2 (pt) 2006-10-27 2013-11-12 Genentech Inc Anticorpors e imunoconjugados e usos para os mesmos
CA2720166A1 (en) * 2008-04-04 2009-10-08 David B. Weiner Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
EP2326350B1 (en) * 2008-09-08 2013-09-04 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010050939A1 (en) * 2008-10-29 2010-05-06 The Trustees Of The University Of Pennsylvania Improved hcv vaccines and methods for using the same
EP2358733B1 (en) * 2008-11-17 2015-07-08 Inovio Pharmaceuticals, Inc. Antigens that elicit immune response against flavivirus and methods of using same
JP6077450B2 (ja) * 2010-11-12 2017-02-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途
WO2013067652A1 (en) * 2011-11-10 2013-05-16 Beijing Advaccine Biotechnology Co., Ltd. Facilitator-dna combination vaccine
EP3518955A4 (en) * 2016-09-30 2020-10-07 The Wistar Institute Of Anatomy And Biology TERT-IMMUNOGENIC COMPOSITIONS AND METHODS OF TREATMENT THEREOF

Also Published As

Publication number Publication date
MX346784B (es) 2017-03-31
KR102131276B1 (ko) 2020-07-08
WO2012065164A3 (en) 2012-07-26
KR102557275B1 (ko) 2023-07-19
JP6310952B2 (ja) 2018-04-11
JP2018030881A (ja) 2018-03-01
EP3909973A3 (en) 2022-01-26
CN106434676B (zh) 2020-10-23
WO2012065164A2 (en) 2012-05-18
JP2014500724A (ja) 2014-01-16
MX2013005195A (es) 2013-08-27
EP3536703A1 (en) 2019-09-11
JP2023171837A (ja) 2023-12-05
CN103314002A (zh) 2013-09-18
CN106434676A (zh) 2017-02-22
US20150150957A1 (en) 2015-06-04
KR20200084067A (ko) 2020-07-09
US20190046621A1 (en) 2019-02-14
CA2817709C (en) 2021-06-01
KR102364214B1 (ko) 2022-02-17
US11045535B2 (en) 2021-06-29
KR20220025242A (ko) 2022-03-03
KR20190096447A (ko) 2019-08-19
MX358725B (es) 2018-09-03
EP2638055A4 (en) 2015-12-30
EA027315B1 (ru) 2017-07-31
EA201390689A1 (ru) 2013-11-29
US9913885B2 (en) 2018-03-13
EP3536703B1 (en) 2021-05-26
BR112013011705B1 (pt) 2022-04-05
US20220016228A1 (en) 2022-01-20
AU2011325893B2 (en) 2016-01-14
CN103314002B (zh) 2016-09-07
BR112013011705A2 (pt) 2018-03-13
AU2011325893A1 (en) 2013-05-30
US8927692B2 (en) 2015-01-06
US11980659B2 (en) 2024-05-14
US20130302361A1 (en) 2013-11-14
JP7142427B2 (ja) 2022-09-27
ES2718846T3 (es) 2019-07-04
US9399056B2 (en) 2016-07-26
SI3536703T1 (sl) 2022-04-29
JP2021045171A (ja) 2021-03-25
EP2638055B1 (en) 2019-01-09
US20160361403A1 (en) 2016-12-15
US20250101399A1 (en) 2025-03-27
JP2016093199A (ja) 2016-05-26
JP2020108396A (ja) 2020-07-16
JP2026012855A (ja) 2026-01-27
KR101939150B1 (ko) 2019-01-17
PL3536703T3 (pl) 2021-10-25
CA2817709A1 (en) 2012-05-18
EP3909973A2 (en) 2021-11-17
DK2638055T3 (en) 2019-04-23
MX421208B (es) 2025-02-10
JP6077450B2 (ja) 2017-02-08
EP2638055A2 (en) 2013-09-18
JP7572152B2 (ja) 2024-10-23
KR102011026B1 (ko) 2019-08-14
MX2018010616A (es) 2022-08-24
KR20170141811A (ko) 2017-12-26
KR20140004098A (ko) 2014-01-10

Similar Documents

Publication Publication Date Title
ZA201303390B (en) Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same
IL280133A (en) Methods and devices for the synthesis of nucleic acids
ZA201307844B (en) Influenza nucleic acid molecules and vaccines made therefrom
IL251697A0 (en) Antibodies against 3erbb and their uses
GB201010557D0 (en) RNA molecules and uses thereof
PT3590949T (pt) Ácidos ribonucleicos contendo n1-metilpseudouracilos e suas utilizações
ZA201207331B (en) Concentrated protein formulations and uses thereof
IL222961A0 (en) Novel dna-dinding proteins and uses thereof
PL2946791T3 (pl) Przeciwciała anty-CD277 i ich zastosowania
SMT201900219T1 (it) Anticorpi anti-s100a4 e relativi usi terapeutici
IL225461B (en) Human antibodies against ccr7, nucleic acids encoding them and preparations containing them
ZA201306009B (en) Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same
SG173751A1 (en) Foxm1 peptides and vaccines containing the same
ZA201406381B (en) Levoisovalerylspiramycin i,ii,iii,and preparations,preparations methods and uses thereof
ZA201303886B (en) Tomm34 peptides and vaccines including the same
ZA201303254B (en) Small viral rna molecules and uses thereof
IL235426A0 (en) Nucleic acid structure and its use
SG10201501857YA (en) Hjurp Peptides And Vaccines Including The Same
IL225552A0 (en) wdhd1 peptides and vaccines containing them
IL225553A0 (en) 54orf18c peptides and vaccines containing them
GB201012000D0 (en) An isolated nucleic acid and uses thereof
GB201019361D0 (en) Biosensor and uses thereof
IL215915A0 (en) Ttk peptides and vaccines including the same